Radiothérapie hyperfractionnée et accélérée dans les cancers de la tête et du cou: résultats des essais de l'EORTC et impact sur la pratique clinique

Jc, Horiot; Bontemps, P.; Begg, A.C.; Fur, R. Le; Bogaert, Walter Van den; Bolla, M.; Nguyen, Tan Dat; Weijngaert, D. van den; Bernier, Jacques; Lusinchi, A.; Stuschke, D; Torrecilla, D. Lopez; Jančar, Boris; Collette, Laurence; Glabbeke, M. van; Piérart, M.

doi:10.1016/s0924-4212(97)86083-5

Cited by 15 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Re-population during the radiotherapy course is being addressed by altered fractionation regimes. The RTOG 4 and EORTC 5 groups have shown in controlled trials that hyperfractionation into twice daily fractions improves local control. Continuous hyperfractionated accelerated radiotherapy (CHART) 4 was investigated in a rigorous national trial with radical daily fractionation as the control arm.…”

mentioning

confidence: 99%

The future of radiotherapy and chemotherapy in head and neck cancer

Bridgewater

Spittle

2000

J. Laryngol. Otol.

View full text Add to dashboard Cite

For the 40 per cent of patients with head and neck cancer who present with stage I and II disease either radiotherapy or surgery can be curative. The remaining 60 per cent have advanced loco-regional disease and even when treated with surgery and radiotherapy the five-year survival is less than 30 per cent. Most patients with relapse have loco-regional disease and second primary tumours have an incidence of three per cent a year.1 Current attempts to improve prognosis include the addition of chemotherapy, the use of brachytherapy and accelerated radiotherapy regimes such as continuous hyperfractionated accelerated radiotherapy (CHART).

show abstract

mentioning

confidence: 99%

The future of radiotherapy and chemotherapy in head and neck cancer

Bridgewater

Spittle

2000

J. Laryngol. Otol.

View full text Add to dashboard Cite

show abstract

“…In Great Britain, 'CHART' (continuous hyperfractionated accelerated radiotherapy) has been notable among these trials, with a total recruitment of nearly 1000 patients. We are waiting further follow-up before full results of this and of some of the other recently completed trials will be available, but enough data has been collected for some preliminary comments to be made (Horiot et al, 1996;Saunders et al, 1996), and one early trial demands a specific mention. The EORTC radiotherapy group conducted a trial of a 'pure' hyperfractionated regimen and compared it in a randomized trial with conventional radiotherapy, given over the same overall time for tumours of the oropharynx (Horiot et al, 1996).…”

mentioning

confidence: 99%

“…We are waiting further follow-up before full results of this and of some of the other recently completed trials will be available, but enough data has been collected for some preliminary comments to be made (Horiot et al, 1996;Saunders et al, 1996), and one early trial demands a specific mention. The EORTC radiotherapy group conducted a trial of a 'pure' hyperfractionated regimen and compared it in a randomized trial with conventional radiotherapy, given over the same overall time for tumours of the oropharynx (Horiot et al, 1996). The control arm were treated with a 'standard' dose of 70 Gy, whereas the hyperfractionated treatment delivered 80.5 Gy in the same overall time, by the expedient of giving two small fractions of 1.15 Gy on each treatment day.…”

mentioning

confidence: 99%